Long-term study of eteplirsen, golodirsen, or casimersen for DMD
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study follows people with Duchenne muscular dystrophy (DMD) who are taking eteplirsen, golodirsen, or casimersen. It aims to understand how these medicines work in everyday life over a long period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Duchenne muscular dystrophy (DMD), confirmed by a genetic test.
- You are currently taking eteplirsen, golodirsen, or casimersen, or plan to start one of these within 6 months.
- You are not taking part in any other research study that tests a new DMD treatment.
- You agree to let the study team use your genetic test results.
- You are willing to follow study procedures and provide information over time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called SGT-003 in boys and men with Duchenne muscular dystrophy who are still able to walk. The treatment aims to deliver a working version of the dystrophin gene to help muscle cells produce the protein they are missing.
This study is checking how safe and effective ELEVIDYS, a gene therapy for Duchenne muscular dystrophy, is when used in everyday clinics. It will help doctors understand more about the treatment's real-world effects and provide care for those who receive it.
This study follows boys with Duchenne muscular dystrophy over time to better understand how the condition changes and how standard treatments affect health and function. It does not appear to test a new medicine, but it may help doctors plan better future care and studies.
This study tests a new medication called KER-065 to see if it helps people with Duchenne Muscular Dystrophy (DMD). It may help boys and men who are still walking, as well as those who use a wheelchair, as long as they are on a stable corticosteroid treatment.
This trial looks at how safely givinostat works over a longer time in people with Duchenne muscular dystrophy (DMD). It mainly checks long-term side effects and tolerability, especially in a specific subgroup of muscle fat levels.
This study is for people with Duchenne muscular dystrophy (DMD) who are taking Givinostat, a daily oral medicine. Researchers will look at real-world data to see how the medicine works in everyday life, including lab results and how it's being used.
Hear when a new Duchenne Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.